Encouraging phase III trials of Janssen’s SYMTUZA

Janssen Pharmaceutical’s phase 3 DIAMOND trial is evaluating the rapid initiation of a single-tablet regimen SYMTUZA for the treatment of human immunodeficiency virus type 1 infection in adults. 109 patients took part in the trial, of which 97 completed the 48 week study. In the primary intent-to-treat analysis, 84% of patients registered undetectable viral loads, while 8% of patients had virologic failure at 48 weeks. Excluding those with missing data, 96% of patients showed undetectable viral loads. 100% of patients registered viral loads of less than 200 c/mL at week 48, with none of the patients having to stop SYMTUZA treatment based on efficacy reasons. No serious related adverse events were recorded.
Richard Nettles, Janssen Scientific Affairs, Janssen Infectious Diseases, medical affairs vice president, said: “The DIAMOND study mirrors real clinical scenarios that physicians face today – including the need to start treatment before lab or baseline resistance test results are available – and highlights the benefits this model of care can bring to those newly diagnosed with HIV. SYMTUZA is the only single-tablet regimen proven in a Phase 3 clinical trial studying the rapid initiation of treatment, further demonstrating it as a treatment option for people new to HIV therapy.”